pomalidomide has been researched along with Carditis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, R; Boise, LH; Chang, A; Kaufman, JL; Khan, MK; Lonial, S; Nasti, TH; Nooka, AK; Parashar, S | 1 |
| Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ | 1 |
1 trial(s) available for pomalidomide and Carditis
| Article | Year |
|---|---|
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Multiple Myeloma; Myocarditis; Progression-Free Survival; Proportional Hazards Models; Recurrence; Stevens-Johnson Syndrome; Survival Rate; Thalidomide; Treatment Outcome | 2019 |
1 other study(ies) available for pomalidomide and Carditis
| Article | Year |
|---|---|
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Dexamethasone; Female; Humans; Immunotherapy; Middle Aged; Multiple Myeloma; Myocarditis; Nivolumab; Off-Label Use; Thalidomide | 2018 |